Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24855086 | 0.88 | CYP3A4 (0.55) | TP53ALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL22230751 | 0.85 | LMNA (0.47) | TP53ALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL630768 | 0.83 | CA1 (0.58) | TP53ALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL5053806 | 0.79 | LMNA (0.43) | TP53ALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL714254 | 0.79 | MAOB (0.46) | TP53ALDH1A1KDM4ELMNACYP3A4 | |
| 3-Methoxycatechol SCHEMBL67332 | 0.78 | TP53 (1.00) | TP53ALDH1A1KDM4ELMNACYP3A4 | |
| 3-Methoxycatechol SCHEMBL29477155 | 0.78 | TP53 (1.00) | TP53ALDH1A1KDM4ELMNACYP3A4 | |
| Guaiacol SCHEMBL27350958 | 0.78 | CA2 (0.95) | TP53ALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL12804048 | 0.78 | MAPT (0.48) | TP53ALDH1A1KDM4ELMNACYP3A4 | |
| SCHEMBL27637325 | 0.77 | TP53 (0.64) | TP53ALDH1A1KDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609065-A1 | PROCESSES FOR PRODUCING 1-BROMO-2 (CYCLOPROPYL METHOXY)-5 FLUORO-4- METHOXYBENZENE | Albemarle Corporation (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012027134-A1 | PROCESSES FOR PRODUCING 1-BROMO-2 (CYCLOPROPYL METHOXY)-5 FLUORO-4- METHOXYBENZENE | ALBEMARLE CORPORATION (US) | 2012-03-01 | — | — | WO | claimed |
| US-20260137083-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2026-05-21 | — | — | US | disclosed |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12501900-B2 | Heterocyclyl pyridazine as fungicidal compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2025-08-12 | — | — | US | disclosed |
| WO-2025026457-A1 | MODIFIED FLAVONE COMPOUNDS AND USE THEREOF | 苏州格兰科医药科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| EP-3405192-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) | 2024-12-11 | — | — | EP | disclosed |
| CN-119080765-A | As fungicidal compounds heterocyclic pyridazines of the compounds | 拜耳公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006057860-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006057869-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006057870-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1732189-A | Ethylene polymer and molded article obtained therefrom | MITSUI CHEMICALS INC (JP) | 2006-02-08 | — | — | CN | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | TP53 4212/4885ALDH1A1 2698/4885KDM4E 1132/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TP53 4494/4885ALDH1A1 355/4885KDM4E 4854/4885 |
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | ABL1, BTK, LYN | TP53 702/4885ALDH1A1 3914/4885KDM4E 1557/4885 |
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | FLT1, KDR, FLT4 | TP53 682/4885ALDH1A1 397/4885KDM4E 3048/4885 |
| US-12501900-B2 | Heterocyclyl pyridazine as fungicidal compounds | PNPO, PDXK, BLVRB | TP53 3322/4885ALDH1A1 2480/4885KDM4E 861/4885 |
| US-20260137083-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | CBR1, CBR3, CYC1 | TP53 4731/4885ALDH1A1 838/4885KDM4E 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.